Opinion

Video

Personalizing Treatment Selection

A key opinion leader in dermatology explains how the presence of type 2 inflammation informs their treatment decisions for atopic dermatitis and prurigo nodularis, while also detailing additional patient-specific factors such as age, comorbidities, and disease severity that influence their therapeutic approach.

  • How does knowing that type 2 inflammation is a cause influence your treatment selection?
  • Beyond identifying the underlying cause, what other patient-specific factors (e.g., age, comorbidities, disease severity) do you consider when selecting treatment regimens for AD or PN?

Newsletter

Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.

Subscribe Now!
Related Videos
5 experts are featured in this series
2 experts in this video
5 experts are featured in this series
4 experts are featured in this series.
4 experts are featured in this series.
Related Content
GLP-1 receptor agonists | Image Credit: K KStock - stock.adobe.com
July 11th 2025

GLP-1 Receptor Agonists Show Promise as Adjunctive Treatment for Ovarian Cancer

Brooke McCormick
Glucagon-like peptide-1 (GLP-1) receptor agonists significantly enhance overall survival in patients with ovarian cancer, offering a promising adjunct to traditional treatments.
managed care cast logo
December 23rd 2024

Five Years Later: Ongoing COVID-19 Challenges, Next Steps

Brooke McCormick
On this episode of Managed Care Cast, we speak with Jenny Han, MD, of Emory School of Medicine and Grady Hospital, about COVID-19, long COVID, and strategies for prevention and care.
Medical personnel filing a syringe needle | Image Credit: MargJohnsonVA - stock.adobe.com.jpeg
July 10th 2025

SGLT2 Inhibitor Offers Kidney Protection and Reduces Heart Failure Risk After Acute Myocardial Infarction

Giuliana Grossi
Secondary analysis findings from the EMPACT-MI trial highlight empagliflozin's significant cardiovascular and kidney benefits when initiated soon after an acute myocardial infarction.
Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi
December 17th 2024

Diving Into Patient Preferences for Blood Cancer Treatments With Dr Sikander Ailawadhi

Three abstracts presented at the 2024 American Society of Hematology annual meeting focused on patient preferences and treatment choices in blood cancers.
COVID-19 3D rendering | Image Credit: Production Perig - stock.adobe.com
July 8th 2025

Severe COVID-19 Linked to Higher Exacerbation, Mortality Risks in Patients With Bronchiectasis

Brooke McCormick
Patients with bronchiectasis face heightened risks of severe exacerbation and mortality after COVID-19 recovery, especially following severe cases.
Paxlovid box | Image Credit: Mike Mareen - stock.adobe.com
July 8th 2025

Encounter-Level Factors Drive Racial Disparities in COVID-19 Treatment Access

Brooke McCormick
Encounter-level factors played a key role in limiting outpatient COVID-19 treatment for Black and Latino patients.

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo